within Pharmacolibrary.Drugs.ATC.C;

model C08DA51
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0010833333333333333,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.3,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600,            
    Vdp             = 0.4,
    k12             = 70,
    k21             = 70
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08DA51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Verapamil is a calcium channel blocker used to treat hypertension, angina pectoris, and certain types of cardiac arrhythmias. The C08DA51 code refers to combinations of verapamil, often with diuretics, as antihypertensive medications. While verapamil is approved and used clinically, specific fixed-dose combination products may have variable regulatory status depending on the country.</p><h4>Pharmacokinetics</h4><p>No dedicated pharmacokinetic studies with model parameters are found in the literature for verapamil-containing combinations under ATC C08DA51. The parameters provided are estimates based on typical oral verapamil pharmacokinetics in healthy adult subjects.</p><h4>References</h4><ol><li><p>Elazab, ST, &amp; Hsu, WH (2021). Effects of verapamil on the pharmacokinetics of ivermectin in rabbits. <i>Journal of veterinary pharmacology and therapeutics</i> 44(3) 397–405. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12919&quot;>10.1111/jvp.12919</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33070345/&quot;>https://pubmed.ncbi.nlm.nih.gov/33070345</a></p></li><li><p>Hamann, SR, et al., &amp; McAllister, RG (1984). Clinical pharmacokinetics of verapamil. <i>Clinical pharmacokinetics</i> 9(1) 26–41. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198409010-00002&quot;>10.2165/00003088-198409010-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6362951/&quot;>https://pubmed.ncbi.nlm.nih.gov/6362951</a></p></li><li><p>Kornberger, R, et al., &amp; Hu, K (2014). Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers. <i>Journal of clinical pharmacology</i> 54(11) 1263–1271. DOI:<a href=&quot;https://doi.org/10.1002/jcph.325&quot;>10.1002/jcph.325</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24788408/&quot;>https://pubmed.ncbi.nlm.nih.gov/24788408</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08DA51;
